Status:
COMPLETED
Immunogenicity and Thrombotic Potential of Circulating Protamine-heparin Complexes in Cardiac Surgery Patients
Lead Sponsor:
Medical University of Vienna
Conditions:
Thrombocytopenia
Antibodies Drug Specific
Eligibility:
All Genders
18-99 years
Brief Summary
The primary aim of this study was to describe the prevalence and time course of the occurrence of protamine/heparin antibodies in patients undergoing cardiac surgery on cardiopulmonary bypass. The se...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- cardiac surgery on cardiopulmonary bypass
Exclusion
- cardiac surgery without cardiopulmonary bypass
- age \< 18 years
- no written consent
Key Trial Info
Start Date :
January 7 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT06565364
Start Date
January 7 2019
End Date
March 31 2023
Last Update
August 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna
Vienna, Austria, 1090